Cargando…

Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands

OBJECTIVE: To assess the cost effectiveness of cetuximab in third-line treatment of patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC) in routine clinical practice compared with best supportive care (BSC). METHODS: Patients (n = 287) with KRAS wt mCRC treated with cetuximab or BSC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uyl-de Groot, Carin A., van Rooijen, Elisabeth M., Punt, Cornelis J. A., Pescott, Chris P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6049844/ https://www.ncbi.nlm.nih.gov/pubmed/30019286 http://dx.doi.org/10.1186/s13561-018-0197-3

Ejemplares similares

Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands
por: van der Linden, Naomi, et al.
Publicado: (2015)

Costs of Newly Funded Proton Therapy Using Time-Driven Activity-Based Costing in The Netherlands
por: Chen, Yi Hsuan, et al.
Publicado: (2023)

Regulatory Approval, Reimbursement, and Clinical Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer in the Netherlands
por: Luyendijk, Marianne, et al.
Publicado: (2023)

Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands
por: Xander, Nicolas S. H., et al.
Publicado: (2023)

Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran
por: Ansaripour, Amir, et al.
Publicado: (2018)

Expanded Access as a source of real‐world data: An overview of FDA and EMA approvals
por: Polak, Tobias B., et al.
Publicado: (2020)

Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model
por: Franken, Mira D., et al.
Publicado: (2020)

Measuring Quality of Life Using Patient-Reported Outcomes in Real-World Metastatic Breast Cancer Patients: The Need for a Standardized Approach
por: Clarijs, Marloes E., et al.
Publicado: (2021)

Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands
por: Kwakman, Johannes J. M., et al.
Publicado: (2017)

Real-world data from expanded access programmes in health technology assessments: a review of NICE technology appraisals
por: Polak, Tobias B, et al.
Publicado: (2022)

Revisiting oral fluoropyrimidine with cetuximab in metastatic colorectal cancer: Real-world data in Chinese population
por: Lam, Ka-On, et al.
Publicado: (2019)

Real-world comparison between weekly versus biweekly dosing of cetuximab for metastatic colorectal cancer
por: Aggarwal, Himani, et al.
Publicado: (2023)

Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments
por: De Groot, S., et al.
Publicado: (2017)

The cost‐effectiveness of dapagliflozin compared to DPP‐4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands
por: Van der Linden, N., et al.
Publicado: (2020)

Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma
por: Bullement, Ash, et al.
Publicado: (2019)

Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer
por: Carvalho, Adriana Camargo, et al.
Publicado: (2017)

Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy
por: Ansaripour, Amir, et al.
Publicado: (2017)

Real-World Metastatic Renal Cell Carcinoma Treatment Patterns and Clinical Outcomes in The Netherlands
por: van Laar, S.A., et al.
Publicado: (2022)

Cost-effectiveness of first line nivolumab-ipilimumab combination therapy for advanced non-small cell lung cancer: A systematic review and methodological quality assessment
por: Zaim, Remziye, et al.
Publicado: (2023)

A Practical Guide for Using Registry Data to Inform Decisions About the Cost Effectiveness of New Cancer Drugs: Lessons Learned from the PHAROS Registry
por: Blommestein, Hedwig M., et al.
Publicado: (2015)

Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer
por: Pander, Jan, et al.
Publicado: (2015)

Hospital-based or home-based administration of oncology drugs? A micro-costing study comparing healthcare and societal costs of hospital-based and home-based subcutaneous administration of trastuzumab
por: Franken, Margreet, et al.
Publicado: (2020)

Cost-effectiveness Analysis of Cetuximab in Treatment of Metastatic Colorectal Cancer in Iranian Pharmaceutical Market
por: Davari, Majid, et al.
Publicado: (2015)

EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer
por: Spindler, Karen-Lise G, et al.
Publicado: (2011)

Cost and cost-effectiveness of adjuvant trastuzumab in the real world setting: A study of the Southeast Netherlands Breast Cancer Consortium
por: Seferina, Shanly C., et al.
Publicado: (2017)

Hospital costs and cosmetic outcome of benign and high-risk breast lesions managed by vacuum-assisted excision versus surgical excision
por: van de Voort, Elles MF, et al.
Publicado: (2022)

Medical Resource Use and Medical Costs for Radiotherapy-Related Adverse Effects: A Systematic Review
por: Chen, Yi Hsuan, et al.
Publicado: (2022)

Statin Use Is Not Associated with Improved Progression Free Survival in Cetuximab Treated KRAS Mutant Metastatic Colorectal Cancer Patients: Results from the CAIRO2 Study
por: Krens, Lisanne L., et al.
Publicado: (2014)

Direct Medical Costs of Advanced Breast Cancer Treatment: A Real-World Study in the Southeast of The Netherlands
por: Schneider, Paul Peter, et al.
Publicado: (2021)

TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck
por: Rubió-Casadevall, Jordi, et al.
Publicado: (2023)

Third-line treatment options in metastatic pancreatic cancer patients: a real-world study
por: Lu, Hong-Rui, et al.
Publicado: (2023)

Cost-effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in Treatment of Active Tuberculosis
por: Rens, Neil E, et al.
Publicado: (2020)

The Cost of Manual Charting
por: Clarke, Becky
Publicado: (2013)

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2020)

Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations
por: Holleman, Marscha S., et al.
Publicado: (2019)

Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab
por: Baas, Jara, et al.
Publicado: (2018)

Cost-Effectiveness Analysis of MammaPrint(®) to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer
por: Luyendijk, Marianne, et al.
Publicado: (2023)

Cetuximab Can Be an Effective and Low-Toxicity Maintenance Treatment Drug in Patients With Metastatic Colorectal Cancer: A Real-World Study of Zhejiang Cancer Hospital
por: Yuan, Meiqin, et al.
Publicado: (2021)

First‐line cetuximab + platinum‐based therapy for recurrent/metastatic head and neck squamous cell carcinoma: A real‐world observational study—ENCORE
por: Le Tourneau, Christophe, et al.
Publicado: (2023)

Cost-Effectiveness of Abemaciclib in Early Breast Cancer Patients: One Size Fits All or Tailoring to Patients’ Needs?
por: Jongbloed, Elisabeth M, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_89qrr86mu8osiiec4ngcdoqn2m